Meet Chinese Doctor. Xiaoyan Ke: Leading Expert in Hematology and Lymphoma Treatment

Meet Chinese Doctor. Xiaoyan Ke: Leading Expert in Hematology and Lymphoma Treatment

Global Healthcare

In the journey of treating hematologic malignancies, for patients in advanced stages with no standard clinical treatment options, seeking medical care abroad or through remote video consultations has become a pathway to new hope. Through these means, patients can connect with top international experts and gain access to new treatment plans and more options. Leading international specialists not only continuously achieve breakthroughs in treatment technologies but also provide personalized treatment recommendations based on the latest research. Next, we are proud to introduce a highly acclaimed and renowned expert in the fields of hematology and lymphoma from China—Professor Ke Xiaoyan.

### Expert Profile

    **Professor Ke Xiaoyan** is the Chief Physician of the Hematology Department at Peking University Third Hospital and serves as the Lead Expert of the Adult Lymphoma Division at the GoBroad Medical (Hematology) Beijing Research Center. She is also the Deputy Director of the Hematology Department at Peking University Health Science Center. Additionally, she holds the position of Chief Consultant for the Adult Lymphoma Department at Beijing GoBroad-Boren Hospital, where she has trained numerous PhD students, establishing herself as one of China’s top experts in hematologic oncology.

    Professor Ke is highly regarded within the Chinese medical community. She has served as the Chairperson of the Hematology Branch of the Chinese Female Physicians Association and currently holds key positions in several authoritative medical organizations. Her academic background and international reputation have earned her wide recognition in the field of hematologic malignancy treatment.

### Areas of Expertise

    Professor Ke has extensive experience in the standardized treatment of lymphoma, targeted chemotherapy, and both autologous and allogeneic hematopoietic stem cell transplantation. She is at the forefront of international research in treating relapsed and refractory lymphomas through second-generation gene sequencing, targeted therapies, and CAR-T cell immunotherapy. Beyond her clinical expertise, she is a leading figure in the molecular diagnosis of malignant blood diseases and the monitoring of minimal residual disease.

### Research Contributions and International Reputation

    Professor Ke has made remarkable achievements in scientific research as well. She has been the principal investigator in more than 70 international multicenter clinical trials and has published over 300 academic papers, including more than 30 influential SCI papers in top-tier international journals, focusing on cutting-edge research in lymphoma and hematologic malignancies. She has authored and contributed to more than 30 authoritative medical books and received over 40 national research grants, significantly advancing the field of hematology.

    In addition to her research work, Professor Ke serves on the editorial boards of several medical journals, including as Deputy Editor-in-Chief of the **Journal of Leukemia & Lymphoma**. She is also a consulting expert for the Ministry of Health and a key member of the Central Health Consultation Committee. As a leading figure in international hematologic oncology research, her studies encompass the molecular mechanisms of lymphoma, immunotherapy, and stem cell transplantation, enhancing China’s standing in global academic research.

### Main Research Focuses

– Standardized treatment of lymphoma

– Molecular diagnosis of malignant blood diseases and monitoring of minimal residual disease

– Research on autologous peripheral blood stem cell transplantation for malignant blood diseases

– Non-myeloablative transplantation and CAR-T cell therapy for refractory relapsed malignant lymphoma

– Research on B7/CD28 signaling and T-cell immune tolerance mechanisms

– Study of the molecular mechanisms of tumor immunity

### Publications and Research Achievements

Professor Ke Xiaoyan has authored several authoritative books in the field of lymphoma, including **Lymphoma** and **Lymphoma Diagnosis and Treatment Manual**. Her key SCI papers include:

1. **Biological and Clinical Influences of NPM1 in AML Patients with DNMT3A Mutations**, *Cancer Management and Research*, 2018.

2. **Clinical and Biological Implications of IDH1/2 in AML with DNMT3A Mutation**, *Cancer Management and Research*, 2018.

3. **High PD-L1 Expression Predicts Poor Prognosis in Diffuse Large B-cell Lymphoma**, *Annals of Hematology*, 2018.

4. **Molecular Predictors of Post-transplant Survival in Acute Myeloid Leukemia**, *Blood Cancer Journal*, 2017.

5. **High Expression of CPNE3 Predicts Adverse Prognosis in AML**, *Cancer Science*, 2017.

6. **High Expression of ETS2 Predicts Poor Prognosis in AML**, *Journal of Translational Medicine*, 2017.

7. **A Minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 Contributes to Leukemogenesis in t(8;21) AML**, *International Journal of Cancer*, 2017.

### Online Consultation and Appointment Information  

Professor Ke currently offers online video consultation services. Patients can make appointments through the following methods:

WhatsApp: Https://wa.me/+8613717959070 

Wechat：doctors0152

Email: doctor.huang@globecancer.com

#Hematology #LymphomaTreatment #AdvancedCancerCare #InternationalConsultation #CAR_TTherapy #PersonalizedMedicine #ProfessorKeXiaoyan #StemCellTransplantation #CancerResearch #GlobalHealthcare

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

4 months ago Lymphoma

2024 ASCO | Relma-cel Achieves a 4-Year OS Rate of 66.7% in Treating R/R LBCL, Making Lymphoma Cure Possible

2024 ASCO | Relma-cel Achieves a 4-Year OS Rate of 66.7% in Treating R/R LBCL, Making Lymphoma Cure Possible

Lymphoma

Over the past few decades, there have been significant advancements in the treatment of hematologic malignancies, particularly with CAR-T cell therapy. Recently, Relma-cel (relmacabtagene autoleucel) showcased promising new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting its remarkable efficacy in treating relapsed/refractory large B-cell lymphoma (R/R LBCL).

### Breakthrough in CAR-T Therapy

Relma-cel is a CD19-targeted CAR-T cell therapy that reprograms a patient’s own T cells to recognize and attack cancer cells. Studies have shown that Relma-cel achieves a 4-year overall survival (OS) rate of 66.7% in patients with R/R LBCL, with the rate soaring to 82.5% for those who achieve complete remission (CR). These results indicate that Relma-cel not only significantly extends survival but also increases the cure rate for these patients.

### The Power of Long-Term Follow-Up Data

The RELIANCE study, one of the largest CAR-T cell therapy studies in China, aims to evaluate the efficacy and safety of Relma-cel in R/R LBCL patients. The latest 4-year follow-up data reveals that 25 patients remain alive, and the median overall survival (OS) has not yet been reached. This milestone offers immense hope for patients and physicians, underscoring the long-term survival benefits of this therapy.

### Balancing Safety and Efficacy

Relma-cel also excels in safety. The incidence rates of ≥3 grade cytokine release syndrome (CRS) and neurotoxicity (NT) are 5.1% and 3.4%, respectively. Compared to other CD19 CAR-T cell therapies, Relma-cel effectively reduces side effects while significantly enhancing efficacy. This success is largely attributed to its unique CAR structure design, which includes a 4-1BB costimulatory domain, a CD28 transmembrane domain, and an optimized hinge region. These features enable Relma-cel to survive longer in the body and enhance its tumor-killing power.

### Future Prospects

As Relma-cel continues to expand its reach, more R/R LBCL patients are expected to benefit from this advanced treatment. Currently, Relma-cel is exploring its potential use in second-line treatment for LBCL and frontline therapy for high-risk LBCL patients. Additionally, it has shown excellent clinical value in treating relapsed/refractory follicular lymphoma (R/R FL) and mantle cell lymphoma (R/R MCL).

Relma-cel’s success not only brings new hope to lymphoma patients but also signifies a new era in the treatment of hematologic malignancies. We look forward to more research findings on Relma-cel, which will bring hope and possibilities for curing lymphoma to patients worldwide.

With Relma-cel, curing lymphoma is no longer an unattainable dream. Let’s anticipate more breakthroughs in this field, bringing new light to the lives of every patient.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#LymphomaTreatment #CAR_TTherapy #CancerResearch #RelmaCel #HopeForPatients #MedicalAdvancements #ASCO2024 #InnovativeTherapies #Survivorship #CureLymphoma